Baseline characteristics of the 490 patients who participated in the trial
| Characteristic | Mean (SD)* | |
|---|---|---|
| Intervention n = 233 | Control n = 257 | |
| Age, yr | 47.5 (10.7) | 47.0 (9.4) |
| Female, no. (%) | 195 (83.7) | 223 (86.8) |
| Triptans used per month during past year | 5.2 (4.3) | 5.1 (3.8) |
| Consultations for migraine in past year | 0.81 (1.2) | 0.80 (1.3) |
| Prophylaxis, no. (%)† | 76 (32.2) | 71 (27.6) |
| β-blocker | 54 (23.6) | 54 (20.6) |
| Sodium valproate | 8 (4.3) | 4 (1.9) |
| Other prophylaxis | 9 (5.2) | 11 (5.4) |
| Headache | n = 229 | n = 254 |
| HIT-6 score | 61.6 (5.5) | 61.9 (5.0) |
| Depressive/anxiety symptoms | n = 228 | n = 250 |
| K10 score | 19.6 (6.8) | 18.4 (5.7) |
| Quality of life | n = 230 | n = 254 |
| EurQol score | 0.80 (0.21) | 0.83 (0.18) |
| Migraine attacks during previous month | n = 219 | n = 235 |
| < 2 attacks/mo, % | 81 (34.8) | 89 (34.6) |
| ≥ 2 attacks/mo, % | 152 (65.2) | 168 (65.4) |
| Absences from work, d/mo | n = 205 | n = 224 |
| 0.47 (1.12) | 0.59 (1.28) | |
| Absences from work in previous 3 months | n = 220 | n = 251 |
| 1.29 (3.13) | 1.48 (2.60) | |
| Triptans used in previous month | n = 198 | n = 212 |
| 5.11 (4.37) | 4.88 (3.61) | |